Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

BioTelemetry

Biotech & Life Sciences · Malvern, United States · Founded 1994 · IPO 2013 Unicorn

At BioTelemetry, we fuel the advancement of mobile health services by providing leading technology and services

Valuation
$2.80B
Market cap · 2026

Investors

5 investors on BioTelemetry's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 5 investors entered at this stage
Biofrontier Partners
Guidant Corporation
IDEO
Sanderling Ventures
Hambrecht & Quist Capital Management

Global footprint

Where BioTelemetry has talent and traffic

AI talent share
0.5% of workforce is AI talent
(3 of 592 staff)
Core AI10.17%
Other AI20.34%
Non-AI workforce58999.49%
Workforce by country
7 countries with
team presence
🇺🇸 United States94.6%
🇲🇰 North Macedonia1%
🇮🇳 India1%
🇧🇴 Bolivia1%
🇦🇷 Argentina1%
Top 5 of 7 shown
Web traffic by country
14K monthly visits
across markets
🇺🇸 United States77.1%
🇮🇳 India10%
🇬🇧 United Kingdom7.1%
🇵🇭 Philippines5%
🇺🇦 Ukraine0%
Top 5 markets shown

Patent intelligence

$5M patent portfolio · 3 active families

Estimated portfolio value
$5M
0.17% of market cap · comparable to top peer MindMaze ($4M)
3 active patent families
Where BioTelemetry innovates Medical treatmentComputer scienceHeart rateEvent basedCentral unit

Where BioTelemetry concentrates vs peers

Each axis is a top-10 topic across BioTelemetry and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

BioTelemetry's 6 investments and acquisitions.

Every disclosed deal where BioTelemetry appeared as a backer or acquirer, 2012–2019. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

6 deals across BioTelemetry's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where BioTelemetry deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        BioTelemetry's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        6 of 6 deals

        Market sentiment

        What the market is saying about BioTelemetry

        An AI-synthesized read of the highest-engagement posts about BioTelemetry on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See BioTelemetry on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.